Vadimezan
Vadimezan (NSC 640488) is a fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan(NSC 640488) induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.
| Catalog Number | T6273 |
| Alternative Name(s) | DMXAA , 5,6-Dimethylxanthenone-4-acetic Acid , NSC 640488 , ASA-404 |
| Research Area | Microbiology/Virology|||Angiogenesis|||Immunology/Inflammation |
| Molecular Formula | C17H14O4 |
| CAS# | 117570-53-3 |
| Purity | 98.50% |
| SMILES | Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C |
| Size | 25 mg |
| Supplier Page | https://www.targetmol.com/compound/Vadimezan |
| Additional Information | https://www.targetmol.com/datasheet/T6273 |